COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls

MLA

Elisa Longinetti, et al. “COVID‐19 Clinical Outcomes and DMT of MS Patients and Population‐based Controls.” Annals of Clinical and Translational Neurology, vol. 9, no. 9, Sept. 2022, pp. 1449–58. EBSCOhost, https://doi.org/10.1002/acn3.51646.

APA

Elisa Longinetti, Hannah Bower, Kyla A McKay, Simon Englund, Joachim Burman, Katharina Fink, Anna Fogdell‐Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer‐Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Johan Mellergård, Tomas Olsson, Fredrik Piehl, & Thomas Frisell. (2022). COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls. Annals of Clinical and Translational Neurology, 9(9), 1449–1458. https://doi.org/10.1002/acn3.51646

Chicago

Elisa Longinetti, Hannah Bower, Kyla A McKay, Simon Englund, Joachim Burman, Katharina Fink, Anna Fogdell‐Hahn, et al. 2022. “COVID‐19 Clinical Outcomes and DMT of MS Patients and Population‐based Controls.” Annals of Clinical and Translational Neurology 9 (9): 1449–58. doi:10.1002/acn3.51646.